Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xilio Therapeutics (XLO) FCF Margin (2024 - 2025)

Xilio Therapeutics (XLO) has disclosed FCF Margin for 2 consecutive years, with 15.29% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 80623.0% to 15.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 12.59% through Dec 2025, up 27767.0% year-over-year, with the annual reading at 12.59% for FY2025, 27767.0% up from the prior year.
  • FCF Margin hit 15.29% in Q4 2025 for Xilio Therapeutics, up from 91.76% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 988.26% in Q1 2025 to a low of 821.52% in Q4 2024.